Brady R Walker, MD | |
2400 Hartman Ln, Springfield, OR 97477-1118 | |
(541) 334-3350 | |
(541) 284-5198 |
Full Name | Brady R Walker |
---|---|
Gender | Male |
Speciality | Urology |
Experience | 28 Years |
Location | 2400 Hartman Ln, Springfield, Oregon |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1346300530 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208800000X | Urology | MD22933 (Oregon) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Sacred Heart Medical Center - Riverbend | Springfield, OR | Hospital |
Peace Harbor Medical Center | Florence, OR | Hospital |
Peacehealth Cottage Grove Community Medical Center | Cottage grove, OR | Hospital |
Bay Area Hospital | Coos bay, OR | Hospital |
Lower Umpqua Hospital District | Reedsport, OR | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Oregon Urology Institute Pc | 6608766399 | 30 |
News Archive
Almost half of those with health conditions said that they skip their medication sometimes, despite knowing its benefits, while more than a quarter are unsure what to do if they experience side-effects, according to COUCH's recently published report, "Are patients receiving value in terms of health literacy?"
Brenda M. Westerhuis et al., in a recent medRxiv* preprint paper, investigate the antibody cross-reactivity - to explain the severe disease. COVID-19 is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Levels of heme oxygenase-1 (HO-1), an antioxidant that protects against reactive oxygen species (damaging oxygen molecules that cause direct tissue injury), become elevated in the lungs of chronic silicosis patients and could represent a new treatment approach for the disease.
Researchers at Moffitt Cancer Center in Tampa, Fla., have found - contrary to previous studies linking inferior outcomes in patients with gastrointestinal malignancies to higher body mass index (BMI) - that in their study of BMI and negative outcomes, there was no such link. They concluded that BMI was not associated with either surgical complications or esophageal cancer patient survival.
ARIAD Pharmaceuticals, Inc., today announced top-line data showing that ridaforolimus, an investigational oral mTOR inhibitor, met the primary endpoint of improved progression-free survival (PFS) compared to placebo in the Phase 3 SUCCEED trial conducted in patients with metastatic soft-tissue or bone sarcomas who previously had a favorable response to chemotherapy.
› Verified 4 days ago
Entity Name | Oregon Urology Institute Pc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1801812078 PECOS PAC ID: 6608766399 Enrollment ID: O20040317000434 |
News Archive
Almost half of those with health conditions said that they skip their medication sometimes, despite knowing its benefits, while more than a quarter are unsure what to do if they experience side-effects, according to COUCH's recently published report, "Are patients receiving value in terms of health literacy?"
Brenda M. Westerhuis et al., in a recent medRxiv* preprint paper, investigate the antibody cross-reactivity - to explain the severe disease. COVID-19 is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Levels of heme oxygenase-1 (HO-1), an antioxidant that protects against reactive oxygen species (damaging oxygen molecules that cause direct tissue injury), become elevated in the lungs of chronic silicosis patients and could represent a new treatment approach for the disease.
Researchers at Moffitt Cancer Center in Tampa, Fla., have found - contrary to previous studies linking inferior outcomes in patients with gastrointestinal malignancies to higher body mass index (BMI) - that in their study of BMI and negative outcomes, there was no such link. They concluded that BMI was not associated with either surgical complications or esophageal cancer patient survival.
ARIAD Pharmaceuticals, Inc., today announced top-line data showing that ridaforolimus, an investigational oral mTOR inhibitor, met the primary endpoint of improved progression-free survival (PFS) compared to placebo in the Phase 3 SUCCEED trial conducted in patients with metastatic soft-tissue or bone sarcomas who previously had a favorable response to chemotherapy.
› Verified 4 days ago
Mailing Address | Practice Location Address |
---|---|
Brady R Walker, MD 2400 Hartman Ln, Springfield, OR 97477-1118 Ph: (541) 334-3350 | Brady R Walker, MD 2400 Hartman Ln, Springfield, OR 97477-1118 Ph: (541) 334-3350 |
News Archive
Almost half of those with health conditions said that they skip their medication sometimes, despite knowing its benefits, while more than a quarter are unsure what to do if they experience side-effects, according to COUCH's recently published report, "Are patients receiving value in terms of health literacy?"
Brenda M. Westerhuis et al., in a recent medRxiv* preprint paper, investigate the antibody cross-reactivity - to explain the severe disease. COVID-19 is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Levels of heme oxygenase-1 (HO-1), an antioxidant that protects against reactive oxygen species (damaging oxygen molecules that cause direct tissue injury), become elevated in the lungs of chronic silicosis patients and could represent a new treatment approach for the disease.
Researchers at Moffitt Cancer Center in Tampa, Fla., have found - contrary to previous studies linking inferior outcomes in patients with gastrointestinal malignancies to higher body mass index (BMI) - that in their study of BMI and negative outcomes, there was no such link. They concluded that BMI was not associated with either surgical complications or esophageal cancer patient survival.
ARIAD Pharmaceuticals, Inc., today announced top-line data showing that ridaforolimus, an investigational oral mTOR inhibitor, met the primary endpoint of improved progression-free survival (PFS) compared to placebo in the Phase 3 SUCCEED trial conducted in patients with metastatic soft-tissue or bone sarcomas who previously had a favorable response to chemotherapy.
› Verified 4 days ago
Jeffrey B Woolsey, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 2400 Hartman Ln, Springfield, OR 97477 Phone: 541-334-3350 Fax: 541-284-5198 | |
Kevin Krughoff, Urology Medicare: Accepting Medicare Assignments Practice Location: 2400 Hartman Ln, Springfield, OR 97477 Phone: 541-736-2934 | |
Dr. Jessica Catherine Lloyd, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 2400 Hartman Ln Ste 100, Springfield, OR 97477 Phone: 541-334-3350 | |
David S Dimarco, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 2400 Hartman Ln, Springfield, OR 97477 Phone: 541-334-3350 Fax: 541-284-5198 | |
Christopher Charles Kyle, MD, MPH Urology Medicare: Accepting Medicare Assignments Practice Location: 2400 Hartman Ln, Springfield, OR 97477 Phone: 541-334-3350 Fax: 541-284-5198 | |
Dawn M Bodell, DO Urology Medicare: Accepting Medicare Assignments Practice Location: 2400 Hartman Ln, Springfield, OR 97477 Phone: 541-334-3350 Fax: 541-284-5198 | |
David Esrig, Urology Medicare: Accepting Medicare Assignments Practice Location: 2400 Hartman Ln, Springfield, OR 97477 Phone: 541-334-3350 Fax: 541-284-5198 |